| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Meeting Report |
Division of Clinical Neurosciences, Department of Neuroimmunology, Guy’s King’s and St. Thomas’ School of Medicine, London, SE1 1UL United Kingdom
ABSTRACT
Neurofibromatosis 1 (NF1) is an autosomal dominant tumor predisposition syndrome in which affected individuals have a greatly increased risk of developing malignant peripheral nerve sheath tumors (MPNSTs). These cancers are difficult to detect and have a poor prognosis. Because patients may present to specialists from widely differing disciplines, the association with NF1 is often not appreciated, and there is no cohesive pattern of care. A multidisciplinary group of 33 clinicians and scientists with specialist knowledge in MPNST and NF1 reviewed the current published and unpublished data in this field, and distilled their collective experience to produce a consensus summary on MPNST in NF1. The known clinical, pathological, and genetic information on MPNST in NF1 was collated, and a database was established to record information in a uniform manner. Subgroups with a higher risk of developing MPNST were identified within the NF1 population. The consortium formulated proposals and guidelines for clinical and pathological diagnosis, surgical management, and medical treatment of MPNST in individuals with NF1. A multidisciplinary team approach to the management of this complex disorder is advocated. Progress can be made by adopting the guidelines proposed by this consortium and by widespread dissemination of standardized information. Collaborative research should be promoted with the aim of harnessing advances in molecular genetics to develop targeted therapies for MPNST in people with NF1.
This article has been cited by other articles:
|
|
 |
|
  C. Gregorian, J. Nakashima, S. M. Dry, P. L. Nghiemphu, K. B. Smith, Y. Ao, J. Dang, G. Lawson, I. K. Mellinghoff, P. S. Mischel, et al. PTEN dosage is essential for neurofibroma development and malignant transformation PNAS, November 17, 2009; 106(46): 19479 - 19484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chowdhry, C. Hughes, R. J. Grimer, V. Sumathi, S. Wilson, and L. Jeys Bone sarcomas arising in patients with neurofibromatosis type 1 J Bone Joint Surg Br, September 1, 2009; 91-B(9): 1223 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. FANG, A. ELAHI, R. C. DENLEY, P. H. RAO, M. F. BRENNAN, and S. C. JHANWAR Molecular Characterization of Permanent Cell Lines from Primary, Metastatic and Recurrent Malignant Peripheral Nerve Sheath Tumors (MPNST) with Underlying Neurofibromatosis-1 Anticancer Res, April 1, 2009; 29(4): 1255 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Kehrer-Sawatzki and D N Cooper Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes? J. Med. Genet., October 1, 2008; 45(10): 622 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Chao, K. A. Stogner-Underwood, J. Kiev, and T. J. Smith Intrathoracic Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis 1 J. Clin. Oncol., May 1, 2008; 26(13): 2216 - 2218. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Johansson, Y. Y. Mahller, M. H. Collins, M.-O. Kim, T. Nobukuni, J. Perentesis, T. P. Cripe, H. A. Lane, S. C. Kozma, G. Thomas, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors Mol. Cancer Ther., May 1, 2008; 7(5): 1237 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ambrosini, H. S. Cheema, S. Seelman, A. Teed, E. B. Sambol, S. Singer, and G. K. Schwartz Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells Mol. Cancer Ther., April 1, 2008; 7(4): 890 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Ferner, J. F. Golding, M. Smith, E. Calonje, W. Jan, V. Sanjayanathan, and M. O'Doherty [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study Ann. Onc., February 1, 2008; 19(2): 390 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E Ferner, S. M Huson, N. Thomas, C. Moss, H. Willshaw, D G. Evans, M. Upadhyaya, R. Towers, M. Gleeson, C. Steiger, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 J. Med. Genet., February 1, 2007; 44(2): 81 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Levy, H. Ripoche, I. Laurendeau, V. Lazar, N. Ortonne, B. Parfait, K. Leroy, J. Wechsler, I. Salmon, P. Wolkenstein, et al. Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1 Clin. Cancer Res., January 15, 2007; 13(2): 398 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Intrathoracic peripheral nerve sheath tumors in patients with neurofibromatosis type 1 (von Recklinghausen disease). J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 736 - 737.
|
|
|
|
 |
|
 S. J. Miller, F. Rangwala, J. Williams, P. Ackerman, S. Kong, A. G. Jegga, S. Kaiser, B. J. Aronow, S. Frahm, L. Kluwe, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res., March 1, 2006; 66(5): 2584 - 2591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aribandi, W.E. Wood, D.M. Elston, and D.L. Weiss CT Features of Plexiform Neurofibroma of the Submandibular Gland AJNR Am. J. Neuroradiol., January 1, 2006; 27(1): 126 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ramanjam, C. Adnams, A. Ndondo, G. Fieggen, K. Fieggen, and J. Wilmshurst Clinical Phenotype of South African Children With Neurofibromatosis 1 J Child Neurol, January 1, 2006; 21(1): 63 - 70. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Barnosky, L. D. Shulman, and A. Talwar MASSIVE INTRATHORACIC MALIGNANT PERIPHERAL NERVE SHEATH TUMOR: WITH TRACHEOBRONCHIAL OBSTRUCTION Chest Meeting Abstracts, October 1, 2005; 128(4): 412S - 413S. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Tucker, P. Wolkenstein, J. Revuz, J. Zeller, and J. M. Friedman Association between benign and malignant peripheral nerve sheath tumors in NF1 Neurology, July 26, 2005; 65(2): 205 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R E Ferner, R A C Hughes, S M Hall, M Upadhyaya, and M R Johnson Neurofibromatous neuropathy in neurofibromatosis 1 (NF1) J. Med. Genet., November 1, 2004; 41(11): 837 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Levy, I. Bieche, K. Leroy, B. Parfait, J. Wechsler, I. Laurendeau, P. Wolkenstein, M. Vidaud, and D. Vidaud Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Identification of a Gene Expression Signature of Poor Prognosis Clin. Cancer Res., June 1, 2004; 10(11): 3763 - 3771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Skotheim, A. Kallioniemi, B. Bjerkhagen, F. Mertens, H. R. Brekke, O. Monni, S. Mousses, N. Mandahl, G. Soeter, J. M. Nesland, et al. Topoisomerase-II{alpha} Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome J. Clin. Oncol., December 15, 2003; 21(24): 4586 - 4591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Castle, M E Baser, S M Huson, D N Cooper, and M Upadhyaya Evaluation of genotype-phenotype correlations in neurofibromatosis type 1 J. Med. Genet., October 1, 2003; 40(10): e109 - 109. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
